The Illness That Whispers Until It Screams: Why Advanced Liver Cancer Is Often Detected So Late - Dr Nirav Vakani

Many prolonged illnesses begin quietly. A person who once carried heavy bags up the stairs easily now feels unusually tired doing the same. Meals grow smaller and the belt around the waist tightens a notch as body weight drops. There is reassurance in routine blood tests and short hospital visits, which don’t find anything to cause alarm. The fatigue and weight loss are attributed to other causes. Then one day, the words ring loud: advanced stage liver cancer.

Recent news about cricketer Rinku Singh’s father’s death due to liver cancer has brought back attention to a disease that rarely announces itself early. Behind the headlines lies a reality that hepatologists are witnessing with increasing regularity: Hepatocellular Carcinoma (HCC).

Understanding Advanced Liver Cancer

Hepatocellular Carcinoma is usually the last chapter of a long, invisible journey of illness, that is usually the outcome of chronic liver disease or cirrhosis.

Chronic Liver Disease begins with sustained inflammation — from Hepatitis B, Hepatitis C, alcohol-related liver injury, or increasingly from Non-Alcoholic Fatty Liver Disease (NAFLD). Persistent inflammation activates fibrogenic pathways, leading to fibrosis. Over time, fibrosis disrupts normal hepatic architecture and progresses to cirrhosis, marked by regenerative cirrhotic nodules and vascular distortion.

Cirrhosis is not merely scarring; it is a premalignant state. Within this altered microenvironment, genetic mutations accumulate, and malignant hepatocytes emerge.

In its early stages, HCC often causes no pain, no dramatic warning. The liver possesses remarkable functional reserve. Even as tumour nodules enlarge, hepatic synthetic function may appear preserved. Alpha-fetoprotein (AFP) levels may remain normal. Ultrasound abnormalities are subtle unless actively sought.

Symptoms tend to appear when complications develop — ascites from portal hypertension, jaundice from hepatic decompensation, confusion from hepatic encephalopathy, or profound cachexia (involuntary muscle loss).

At this point, disease staging under the Barcelona Clinic Liver Cancer (BCLC) system frequently categorises the tumour as intermediate or advanced. What a patient experiences as “sudden deterioration” is often the tipping point of years of silent progression.

Why Diagnosis Happens So Late

Late detection reflects missed surveillance rather than sudden onset. Fatigue is dismissed as ageing. Loss of appetite is blamed on stress. Abdominal distension is rationalised until ascites becomes visible. Jaundice is noticed only when bilirubin levels rise significantly.

Patients with cirrhosis require six-monthly ultrasound screening with AFP monitoring. Yet adherence remains inconsistent. Many individuals with chronic Hepatitis B or Hepatitis C remain undiagnosed. NAFLD, driven by obesity, insulin resistance, and metabolic syndrome, affects individuals who may never consume alcohol and therefore never suspect liver disease.

Stigma also silences conversation. Liver disease is often wrongly equated solely with alcohol misuse, leading to denial and delayed consultation.

Certain groups carry particularly high risk:

● Chronic Hepatitis B or Hepatitis C infection

● Alcohol-related liver disease

● NAFLD or Non-Alcoholic Steatohepatitis (NASH)

● Established cirrhosis of any cause

● Family history of hepatocellular carcinoma

● Unexplained weight loss, jaundice, or new-onset ascites

Without structured surveillance, HCC is frequently detected only when tumour burden increases or vascular invasion occurs.

Treatment in Advanced Stages

When diagnosed early, HCC may be amenable to surgical resection or orthotopic liver transplantation — interventions with curative potential.

In advanced disease, management shifts to control rather than cure. Transarterial Chemoembolisation (TACE) targets tumour-feeding arteries. Systemic targeted therapies such as Sorafenib and Lenvatinib inhibit angiogenic pathways. Immunotherapy using checkpoint inhibitors has improved outcomes in selected patients.

However, therapeutic options are profoundly influenced by hepatic reserve. Once hepatic decompensation manifests – refractory ascites, variceal bleeding, coagulopathy – tolerance to aggressive therapy diminishes. At that stage, integrating palliative care becomes essential to manage pain, dyspnea (tightening of chest/ shortness of breath), and encephalopathy while preserving dignity.

The Emotional Cost Behind the Diagnosis

Advanced liver cancer reshapes a household. Hospital corridors replace family gatherings. Caregivers learn to monitor fluid intake, administer lactulose for encephalopathy, and recognise early signs of variceal bleeding. Financial strain compounds emotional exhaustion.

What lingers most heavily is hindsight — the ultrasound that was postponed, the hepatitis screening that never got done, the metabolic risk factors that were ignored. The tragedy is not the malignancy alone; it is all the years when the disease could have been detected earlier.

Breaking the Silence

Hepatocellular Carcinoma is often preventable or at least detectable at a stage where intervention is meaningful.

Six-monthly ultrasound surveillance for cirrhotic patients, regular AFP monitoring, early antiviral therapy for Hepatitis B and C, metabolic risk reduction in NAFLD, and universal Hepatitis B vaccination remain powerful safeguards.

The liver rarely demands attention loudly. It absorbs injury quietly, compensates generously, but fails gradually. Patients and families deserve to hear about cirrhosis first before they hear about liver cancer. Vigilance transforms prolonged illness from inevitability into opportunity.

Advanced liver cancer should not be the first conversation about liver health. Early screening can replace shock with preparedness, and in many cases, replace loss with a chance to survive.

Disclaimer: The views expressed in this article are of the author and not of Health Dialogues. The Editorial/Content team of Health Dialogues has not contributed to the writing/editing/packaging of this article.